In nonalcoholic steatohepatitis (NASH) and simple steatosis, treatment of mice with the PPAR activator Wy-14,643 protects steatotic livers against I/R injury, and the benefits of this treatment potentially occur through the dampening of adhesion molecule and cytokine responses and activation of nuclear factor kappa B (NF-κB) and IL-6 production [25]. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatohepatitis.